

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER
<b>TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371</b>		JIANG4A
		U.S. APPLICATION NO. (If known, see 37 CFR 1.5)
		<b>10/502085</b>
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY CLAIMED
<b>PCT/CA03/00135</b>	<b>February 4, 2003</b>	<b>February 4, 2002</b>
TITLE OF INVENTION		
<b>IMMUNOSTIMULATORY, COVLENTLY LIPIDATED OLIGONUCLEOTIDES</b>		
APPLICANT(S) FOR DO/EO/US		
<b>Zi-Hua JIANG et al.</b>		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</li> <li>4. <input type="checkbox"/> The US has been elected in a Demand by the expiration of 19 months from the priority date (PCT Article 31).</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is attached hereto (required only if not transmitted by the International Bureau).</li> <li>b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).</li> <li>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. <input type="checkbox"/> have been communicated by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input checked="" type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</li> <li>10. <input type="checkbox"/> An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li> </ol>		
Items 11. to 16. below concern document(s) or information included:		
<ol style="list-style-type: none"> <li>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li>12. <input type="checkbox"/> An Assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>13. <input type="checkbox"/> A FIRST preliminary amendment.</li> <li><input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</li> <li>14. <input type="checkbox"/> A substitute specification.</li> <li>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</li> <li>16. <input checked="" type="checkbox"/> Other items or information: <ol style="list-style-type: none"> <li><input checked="" type="checkbox"/> Courtesy copy of the International Application as filed.</li> <li><input checked="" type="checkbox"/> Courtesy copy of the first page of the International Publication (WO 03/066649 A1).</li> <li><input checked="" type="checkbox"/> Application Data Sheet</li> <li><input checked="" type="checkbox"/> Formal drawings, 28 sheets, Figures 1-28.</li> <li><input checked="" type="checkbox"/> Courtesy Copy of the International Search Report.</li> <li><input checked="" type="checkbox"/> The application is (or will be) assigned to: BIOMIRA INC. whose address is 20011-94 Street, Edmonton, Alberta T6N 1H1 (CA).</li> </ol> </li> </ol>		

U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <div style="font-size: 24pt; font-weight: bold;">10/502085</div>		International Application No. <b>PCT/CA03/00135</b>		Attorney's Docket No. <b>JIANG4A</b>	
---	--	--	--	---	--

  

17. [xx] The following fees are submitted: <b>BASIC NATIONAL FEE (37 CFR 1.492 (a)(1)-(5):</b> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO..... <b>\$1080.00</b>  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO..... <b>\$920.00</b>  International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO..... <b>\$770.00</b>  International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4)..... <b>\$730.00</b>  International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4)..... <b>\$100.00</b>  <div style="text-align: right;"><b>ENTER APPROPRIATE BASIC FEE AMOUNT =</b></div>	<div style="border: 1px solid black; padding: 2px;"><b>CALCULATIONS PTO USE ONLY</b></div>																					
Surcharge of <b>\$130.00</b> for furnishing the oath or declaration later than [ ] 20 [ ] 30 months from the earliest claimed priority date (37 CFR 1.492(e)).	\$																					
<table border="1" style="width:100%; border-collapse: collapse;"> <tr> <th style="width:30%;">Claims as Originally Presented</th> <th style="width:15%;">Number Filed</th> <th style="width:15%;">Number Extra</th> <th style="width:15%;">Rate</th> <th style="width:25%;"></th> </tr> <tr> <td>Total Claims</td> <td>106 - 20</td> <td>86</td> <td>X \$18.00</td> <td>\$1,548.00</td> </tr> <tr> <td>Independent Claims</td> <td>5- 3</td> <td>2</td> <td>X \$86.00</td> <td>\$172.00</td> </tr> <tr> <td colspan="3">Multiple Dependent Claims (if applicable)</td> <td>+\$290.00</td> <td>\$</td> </tr> </table>	Claims as Originally Presented	Number Filed	Number Extra	Rate		Total Claims	106 - 20	86	X \$18.00	\$1,548.00	Independent Claims	5- 3	2	X \$86.00	\$172.00	Multiple Dependent Claims (if applicable)			+\$290.00	\$		
Claims as Originally Presented	Number Filed	Number Extra	Rate																			
Total Claims	106 - 20	86	X \$18.00	\$1,548.00																		
Independent Claims	5- 3	2	X \$86.00	\$172.00																		
Multiple Dependent Claims (if applicable)			+\$290.00	\$																		
<b>TOTAL OF ABOVE CALCULATIONS =</b>		\$920.00																				
<table border="1" style="width:100%; border-collapse: collapse;"> <tr> <th style="width:30%;">Claims After Post Filing Prel. Amend</th> <th style="width:15%;">Number Filed</th> <th style="width:15%;">Number Extra</th> <th style="width:15%;">Rate</th> <th style="width:25%;"></th> </tr> <tr> <td>Total Claims</td> <td>- 20</td> <td></td> <td>X \$18.00</td> <td>\$</td> </tr> <tr> <td>Independent Claims</td> <td>- 3</td> <td></td> <td>X \$86.00</td> <td>\$</td> </tr> </table>	Claims After Post Filing Prel. Amend	Number Filed	Number Extra	Rate		Total Claims	- 20		X \$18.00	\$	Independent Claims	- 3		X \$86.00	\$							
Claims After Post Filing Prel. Amend	Number Filed	Number Extra	Rate																			
Total Claims	- 20		X \$18.00	\$																		
Independent Claims	- 3		X \$86.00	\$																		
<b>TOTAL OF ABOVE CALCULATIONS =</b>		\$920.00																				
Reduction of 1/2 for filing by small entity, if applicable. Applicant claims small entity status. See 37 CFR 1.27.		\$																				
<b>SUBTOTAL =</b>		\$920.00																				
Processing fee of <b>\$130.00</b> for furnishing the English translation later than [ ] 20 [ ] 30 months from the earliest claimed priority date (37 CFR 1.492(f)).		\$																				
<b>TOTAL NATIONAL FEE =</b>		\$920.00																				
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). <b>\$40.00</b> per property +		\$																				
<b>TOTAL FEES ENCLOSED =</b>		\$920.00																				
		<table border="1" style="width:100%; border-collapse: collapse;"> <tr> <td style="width:80%;"><b>Amount to be:</b></td> <td style="width:20%; text-align: center;">\$</td> </tr> <tr> <td style="text-align: center;"><b>refunded</b></td> <td></td> </tr> <tr> <td style="text-align: center;"><b>charged</b></td> <td style="text-align: center;">\$</td> </tr> </table>	<b>Amount to be:</b>	\$	<b>refunded</b>		<b>charged</b>	\$														
<b>Amount to be:</b>	\$																					
<b>refunded</b>																						
<b>charged</b>	\$																					

  

a. [ ] A check in the amount of \$\_\_\_\_\_ to cover the above fees is enclosed.

b. [X] Credit Card Payment Form (PTO-2038), authorizing payment in the amount of \$ 920.00, is attached. At this time no authorization is given to charge any additional fees relating to extra claims, etc. However, if a deficiency exists in the basic filing fee, please charge said deficiency in the filing fee to Deposit Account No. 02-4035.

c. [ ] Please charge my Deposit Account No. 02-4035 in the amount of \$\_\_\_\_\_ to cover the above fees.  
 A duplicate copy of this sheet is enclosed.

d. [ ] The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-4035. A duplicate copy of this sheet is enclosed.

**NOTE:** Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

**BROWDY AND NEIMARK, P.L.L.C.**  
**624 NINTH STREET, N.W., SUITE 300**  
**WASHINGTON, D.C. 20001**  
**TEL: (202) 628-5197**  
**FAX: (202) 737-3528**  
**Date of this submission: July 22, 2004**

SIGNATURE  
 Iver P. Cooper  
 NAME  
 28,005  
 REGISTRATION NUMBER  
 IPC:ccw